Cardinal Health
Company Profile
| Publication Date | February 2007 |
|---|---|
| Publisher | Datamonitor |
| Product Type | Report |
| Pages | 56 |
| ISBN Number | not applicable |
| Product Code | DAT03284 |
Summary
Introduction
This Company Profile examines the performance of Cardinal Health in the medical device sector. The profile encompasses global company strategy and portfolio analysis, and an assessment of financial performance.
Reasons to Purchase
- Analyze Cardinal Health's medical devices portfolio, strategy and financial performance
- Benchmark Cardinal Health's performance against key rivals in the medical devices sector
Content
- Executive Summary
- Key findings
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Chapter 1 Company Overview
- Background
- Key corporate developments
- Corporate structure
- Geographic focus
- Chapter 2 Key Services
- Key segments
- Supply Chain Services - Pharmaceutical
- The Nuclear Pharmacy Services
- Suppy Chain Services - Medical
- Medical Products Manufacturing
- Pharmaceutical Technologies and Services
- Clinical Technologies and Services
- Pyxis
- Alaris
- Key competitors
- Pharmaceutical Distribution and Provider Services
- McKesson Corporation
- AmerisourceBergen Corporation
- Medical Products and Services
- Pharmaceutical Technologies and Services
- GE Healthcare
- Mallinckrodt
- Clinical Technologies and Services
- Chapter 3 M&a Activity
- Key strategies
- Planned divestiture of the Pharmaceutical Technologies & Services
- Significant interest in Automation & Information
- M&A activity, 2002-06
- Acquisitions in 2006
- Care Fusion
- MedMined
- Regional Nuclear Pharmaceuticals
- The F. Dohmen Co.
- Denver Biomedical
- ParMed Pharmaceuticals
- Oncology Therapeutics Network (OTN)
- Other key acquisitions
- Syncor
- Alaris Medical Systems
- Deals and alliances, 2002-06
- R&D
- Distribution and supply
- Manufacturing
- Chapter 4 Financial Performance
- Analysis of historic sales performance by business sector
- Financial analysis
- Revenue & growth rate analysis
- Operating revenue and cost analysis, 2004-06
- Global restructuring program
- Selling, general and administrative expenses
- Operating revenue/cost analysis
- Liquidity
- Return on Capital Employed
- Debt to Equity
- Chapter 5 Future Outlook
- Cardinal Health
- Appendix
- Reference
- List of Tables
- Table 1: Key Cardinal Healthcare timeline
- Table 2: Acquisitions between 2002-2006
- Table 3: Deals and alliances (R&D) between 2002-2006
- Table 4: Deals and alliances (distribution & supply) between 2002-2006
- Table 5: Deals and alliances (manufacturing) between 2002-2006
- Table 6: Cardinal Health's revenues by segment, 2005-2006
- Table 7: Operating revenue/cost analysis ($m), 2004-06
- Table 8: S,G&A analysis, 2004-06
- Table 9: Operating cost ratio analysis (% of total revenues), 2004-06
- Table 10: Return on capital employed (ROCE), 2005-06
- Table 11: Debt-to-equity ratio, 2005-06
- List of Figures
- Figure 1: SWOT analysis of Cardinal Health
- Figure 2: Cardinal Health's core businesses and segments
- Figure 3: Types of acquisitions by Cardinal Health by operating segment between 1980-2006
- Figure 4: Type of acquisitions by Cardinal Health by operating segment between 2002-2006
- Figure 5: Cardinal Health's revenues by segment, 2005-2006
- Figure 6: Cardinal Health's operating earnings by segment, 2005-2006
- Figure 7: Revenue & growth rate ($m), 2002-2006
- Figure 8: Operating revenue/cost analysis ($m), 2004-06
- Figure 9: S,G&A analysis, 2004-06
- Figure 10: Operating cost ratio analysis (% of total revenues), 2004-06
- Figure 11: Operating cost ratio vs. peer set, 2004-06
- Figure 12: Cardinal Health's liquid assets versus total liabilities, 2005-2006
- Figure 13: ROCE vs. peer set, 2006
- Figure 14: Debt-to-equity ratio vs. peer, 2005-06
About this Product
Delivery Details
PDF:Delivered by email usually within 4 to 8 UK business hours.
PRINT/CD-ROM:Despatched within 1 to 2 working days.
Related Products
- AstraZeneca’s Crestor Could Revolutionise Heart Disease Treatment >>
- Sanofi-Aventis and Pfizer Stop Development of a Class of Anti-obesity drugs >>
- Pharma Companies turn Webwards to Recruit Patients as 90% of Clinical Trials Face Delay >>
- Have your Healthcare Costs Reduced with Personalized Healthcare >>
Animal / Veterinary
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Chemicals
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Market Publishers
Meet Us
Jobs
Contact Us
Categories and Subcategories















